Castoria Gabriella, Auricchio Ferdinando, Migliaccio Antimo
Department of Biochemistry, Biophysics, and General Pathology, University of Campania "Luigi Vanvitelli," Naples, Italy
Department of Biochemistry, Biophysics, and General Pathology, University of Campania "Luigi Vanvitelli," Naples, Italy.
FASEB J. 2017 Apr;31(4):1289-1300. doi: 10.1096/fj.201601047R. Epub 2016 Dec 28.
In this review, we focus on the role played by the protein partners of ligand-activated extranuclear androgen receptor (AR) in the final effects of hormone action, such as proliferation, migration, and neuritogenesis. The choice of AR partner, at least in part, depends on cell type. Androgen-activated receptor directly associates with cytoplasmic Src tyrosine kinase in epithelial cells, whereas in mesenchymal and neuronal cells, it prevalently interacts with filamin A. In the former, proliferation represents the final hormonal outcome, whereas in the latter, either migration or neuritogenesis, respectively, occurs. Furthermore, AR partner filamin A is replaced with Src when mesenchymal cells are stimulated with very low androgen concentrations. Consequently, the migratory effect is replaced by mitogenesis. Use of peptides that prevent receptor/partner assembly abolishes the effects that are dependent on their association and offers new therapeutic approaches to AR-related diseases. Perturbation of migration is often associated with metastatic spreading in cancer. In turn, cell cycle aberration causes tumors to grow faster, whereas toxic signaling triggers neurodegenerative events in the CNS. Here, we provide examples of new tools that interfere in rapid androgen effects, including migration, proliferation, and neuronal differentiation, together with their potential therapeutic applications in AR-dependent diseases-mainly prostate cancer and neurodegenerative disorders.-Castoria, G., Auricchio, F., Migliaccio, A. Extranuclear partners of androgen receptor: at the crossroads of proliferation, migration, and neuritogenesis.
在本综述中,我们聚焦于配体激活的核外雄激素受体(AR)的蛋白质伴侣在激素作用的最终效应(如增殖、迁移和神经突形成)中所起的作用。AR伴侣的选择至少部分取决于细胞类型。雄激素激活的受体在上皮细胞中直接与细胞质Src酪氨酸激酶结合,而在间充质细胞和神经元细胞中,它主要与细丝蛋白A相互作用。在前者中,增殖是最终的激素效应,而在后者中,分别发生迁移或神经突形成。此外,当用极低浓度的雄激素刺激间充质细胞时,AR伴侣细丝蛋白A会被Src取代。因此,迁移效应会被有丝分裂所取代。使用能阻止受体/伴侣组装的肽可消除依赖于它们结合的效应,并为AR相关疾病提供新的治疗方法。迁移紊乱通常与癌症的转移扩散有关。反过来,细胞周期异常会导致肿瘤生长加快,而毒性信号会引发中枢神经系统中的神经退行性事件。在此,我们提供了一些干扰雄激素快速效应(包括迁移、增殖和神经元分化)的新工具的实例,以及它们在AR相关疾病(主要是前列腺癌和神经退行性疾病)中的潜在治疗应用。-卡斯托里亚,G.,奥里基奥,F.,米利亚乔,A.雄激素受体的核外伴侣:处于增殖、迁移和神经突形成的交叉点